O TYM ODCINKU
Dr. Remo Panaccione, an internationally recognized expert in clinical trials discusses the recent data on vedolizumab and anti-IL23 therapies and how those changes impact clinical decision making in IBD
Język angielski
Stany Zjednoczone
TRANSKRYPCJA 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
WYSZUKAJ MINIONE ODCINKI
Wyszukaj minione odcinki IBD Essentials.
INNE ODCINKI W TYM PODCASCIE
Pradeep Bhandari from Portsmouth (UK) on recent BSGE guidelines of chromoendoscopy, co-hosted by Raf Bisschops.
Matthieu Allez, Montreal, talks about the management of postoperative Crohn's disease, prediction of relapse rates, monitoring strategies in the postoperative setting, risk factors for postoperative recurrence and potential strategies to prevent recurrence
Bruce Sands, Mount Sinai Hospital New York City, USA, talks about his biography and personal pathway in IBD and options of breaking the therapeutic ceiling in IBD including combination therapy, treat to target and early treatment
Jean-Fred Colombel, Mount Sinai Hospital New York City, USA, talks about his biography and personal pathway in IBD and options of very early diagnosis of IBD and strategies to prevent the onset of IBD (interception) and early management of IBD
Zastrzeżenie: Podcast i grafika osadzone na tej stronie pochodzą z Axel Dignaß, który jest własnością jego właściciela i nie jest powiązany ani wspierany przez Listen Notes, Inc.
EDYTUJ
Dziękujemy za pomoc w aktualizowaniu podcastowej bazy danych.
